Structure Therapeutics Inc. Operating Income
Structure Therapeutics Inc. (GPCR) reported Operating Income of -$118.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Structure Therapeutics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$118.63M.
- Structure Therapeutics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$89.38M.
- Structure Therapeutics Inc. operating income (loss) for the quarter ending 2025-12-31 was $23.99M.
- Structure Therapeutics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$73.79M.
- Structure Therapeutics Inc. operating income (loss) for fiscal 2025 was -$176.56M.
- Structure Therapeutics Inc. operating income (loss) for fiscal 2024 was -$158.23M.
- Structure Therapeutics Inc. operating income (loss) for fiscal 2023 was -$102.78M.
- Structure Therapeutics Inc. operating income (loss) for fiscal 2022 was -$52.56M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$118.63M 10-Q · filed 2026-08-06 | -$208.01M 10-Q · filed 2026-08-06 | -$184.02M derived: sum of 3 quarters · filed 2026-08-06 | -$257.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$89.38M 10-Q · filed 2026-05-07 | -$65.39M derived: sum of 2 quarters · filed 2026-05-07 | -$139.18M derived: sum of 3 quarters · filed 2026-05-07 | -$209.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $23.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$49.80M derived: sum of 2 quarters · filed 2026-02-26 | -$120.25M derived: sum of 3 quarters · filed 2026-08-06 | -$176.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$73.79M 10-Q · filed 2025-11-06 | -$144.24M derived: sum of 2 quarters · filed 2026-08-06 | -$200.55M 10-Q · filed 2025-11-06 | -$247.61M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$70.45M 10-Q · filed 2026-08-06 | -$126.76M 10-Q · filed 2026-08-06 | -$173.82M derived: sum of 3 quarters · filed 2026-08-06 | -$219.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$56.31M 10-Q · filed 2026-05-07 | -$103.37M derived: sum of 2 quarters · filed 2026-05-07 | -$149.21M derived: sum of 3 quarters · filed 2026-05-07 | -$182.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$47.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$92.90M derived: sum of 2 quarters · filed 2026-02-26 | -$126.21M derived: sum of 3 quarters · filed 2026-02-26 | -$158.23M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$45.84M 10-Q · filed 2025-11-06 | -$79.15M derived: sum of 2 quarters · filed 2025-11-06 | -$111.17M 10-Q · filed 2025-11-06 | -$142.16M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$33.32M 10-Q · filed 2025-08-06 | -$65.33M 10-Q · filed 2025-08-06 | -$96.33M derived: sum of 3 quarters · filed 2026-02-26 | -$122.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$32.02M 10-Q · filed 2025-05-08 | -$63.01M derived: sum of 2 quarters · filed 2026-02-26 | -$89.15M derived: sum of 3 quarters · filed 2026-02-26 | -$115.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$30.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$57.14M derived: sum of 2 quarters · filed 2026-02-26 | -$83.13M derived: sum of 3 quarters · filed 2026-02-26 | -$102.78M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$26.14M 10-Q · filed 2024-11-13 | -$52.13M derived: sum of 2 quarters · filed 2024-11-13 | -$71.78M 10-Q · filed 2024-11-13 | -$84.74M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$25.99M 10-Q · filed 2024-08-08 | -$45.64M 10-Q · filed 2024-08-08 | -$58.59M derived: sum of 3 quarters · filed 2024-08-08 | -$71.28M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$19.65M 10-Q · filed 2024-05-09 | -$32.60M derived: sum of 2 quarters · filed 2024-05-09 | -$45.30M derived: sum of 3 quarters · filed 2024-05-09 | -$59.26M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$25.65M derived: sum of 2 quarters · filed 2024-03-08 | -$39.61M derived: sum of 3 quarters · filed 2024-03-08 | -$52.56M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$12.69M 10-Q · filed 2023-11-17 | -$26.65M derived: sum of 2 quarters · filed 2023-11-17 | -$39.60M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$13.96M 10-Q/A · filed 2023-11-17 | -$26.91M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$12.95M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |